

CD19

Research Grade Inebilizumab

Catalog No.	DHD10802A DHD10802B	Quantity:	100 µg 1.0 mg
Alternate Names:	CD19, MEDI-551, CAS: 1299440-37-1		
Description:	Research Grade Inebilizumab is a humanized monoclonal antibody directed against Human B-lymphocyte antigen CD19		
UniProt ID (target):	P15391		
Target:	Human B-lymphocyte antigen CD19		
Concentration:	1.0 mg/ml, lot specific		
Source:	XtenCHO		
Isotype:	Human IgG1 kappa		
Formulation:	Sterile-filtered 0.01 M PBS, pH 7.4		
Purity:	> 95% by SDS-PAGE		
Endotoxin Level:	≤ 0.01 EU/µg by LAL analysis		
Purification:	Protein A/G affinity chromatography		
INN:	Inebilizumab		
Applications:	Functional studies		
Storage & Stability:	Store at 2-8°C for up to 1 week, or in working aliquots at -20°C to -80°C for up to 1 year. Avoid freeze/thaw cycles.		

NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.

